Announcement PDF RNS Number : 6939P N4 Pharma PLC 23 May 2024 N4 Pharma plc ("N4 Pharma" or the "Company") Result of Annual General Meeting N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. Resolution Ordinary Resolution 1 To receive the annual report and audited accounts for the year ended 31 December 2023 Ordinary Resolution 2 To re-elect Nigel Theobald as a Director of the Company Ordinary Resolution 3 To re-elect David Templeton as a Director of the Company Ordinary Resolution 4 To re-appoint Saffery Champness LLP as the Companyʼs auditor and to authorise the Directors to determine their remuneration Ordinary Resolution 5 To authorise the Directors to allot shares Special Resolution 6 To disapply preemption rights For For% Against 20,612,844 99.93% 13,980 20,605,744 99.32% 20,605,744 Against% Total Witheld votes* 0.07% 20,626,824 296,841 141,080 0.68% 20,746,824 176,841 99.32% 141,080 0.68% 20,746,824 176,841 20,605,644 99.32% 140,980 0.68% 20,746,624 177,041 20,559,085 99.10% 187,539 0.90% 20,746,624 177,041 20,506,310 99.00% 207,439 1.00% 20,713,749 209,916 *Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution. For more information please contact: N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director investors.n4pharma.com SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44(0)20 3470 0470 InvestorHub Engage with us directly at N4 Pharma Investor Hub Sign up at investors.n4pharma.com Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope Tel: +44(0)20 3657 0050 https://investors.n4pharma.com/link/Ky0AZe About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market. For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGBBGDUIBDDGSX